Biopharma SPAC Jiya Acquisition priced its $100M IPO. The company intends to start trading today on the Nasdaq under the symbol “JYAC”. The company in earlier filings has said it may raise up to $25 million more at the closing of any merger under terms of a forward purchase agreement. Notice of effectiveness.
Related Posts
Software Acquisition Group III Closes $200M IPO
The SPAC intends to focus on software companies, especially those targeting enterprise vertical sectors owned by private equity and venture capital firms as well as corporate carve-outs.
Stable Road Files Interview with President of Merger Partner Momentus
If Stable Road shareholders approve the merger, Momentus would become the first publicly listed space infrastructure company.
Avista Public Acquisition II Files S-4 on $850M OmniAb Deal with Ligand
The combination of OmniAb and AHPA is structured to guarantee a minimum of $130 million in gross cash.
Vision Sensing Acquisition Shareholders OK 6-Month Extension on Closing Mediforum Deal
The SPAC has a merger agreement with Mediforum, a biomedical company developing treatments for Alzheimer’s and memory enhancement. Established in 2015, Mediforum is headquartered in Seoul, South Korea.